(Reuters) – GlaxoSmithKline Plc and iTeos Therapeutics will develop and commercialize iTeos’ potential treatment for patients with cancer, the companies said on Monday.
iTeos will receive a $625 million upfront payment.
(Reporting by Vishwadha Chander in Bengaluru; Editing by Devika Syamnath)
